Could a stool pill tame ulcerative colitis? early trial begins
NCT ID NCT05852574
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 41 times
Summary
This early study tests CP101, an oral drug made from healthy donor stool, in 30 adults with mild-to-moderate ulcerative colitis. The goal is to see if it safely restores healthy gut bacteria and improves symptoms. Participants get either a short or extended course of CP101 and are followed for 24 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CP101 (a microbiome drug made from donor stool)
What this could lead to
If it works, this could point toward a new way to treat ulcerative colitis by repairing gut bacteria.
What could go wrong
This is a very early Phase 1 trial with only 30 people, so it may not show clear benefit. The treatment is still experimental and safety is the main focus.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.